Chapter 41 — Further Reading

This chapter is about culture, which means most of what has been written on it is journalism, commentary, or opinion rather than evidence. The tiering below matters more here than in almost any other chapter of this book, and the honest position is that Tier 1 is short and Tier 2 is long. That imbalance is itself the chapter's argument.

Tier 1 — Verified canonical

Primary documents and peer-reviewed literature. Citations here are checkable and the specifics are believed accurate as of writing.

The labels themselves — the single most useful reading in this chapter. FDA-approved prescribing information for Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound, available through DailyMed (dailymed.nlm.nih.gov) and Drugs@FDA (accessdata.fda.gov). Reading two labels for the same molecule side by side does more for §41.2 than any commentary. Note the indication statements, the product identity, and the fact that labels are revised — every statement about approval carries a date.

Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384(11):989–1002. (The STEP 1 trial.) Background for what the public conversation is a compression of; Chapter 8 works through it properly.

Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387(3):205–216. (SURMOUNT-1.) The second molecule under the one word.

Bossuyt PM, et al. "STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies." BMJ. 2015;351:h5527. The checklist behind §41.3's 🔬 callout. Read the item list and then ask what a photograph-based judgment would supply for each item. The answer is the section.

FDA Drug Shortages Database (accessdata.fda.gov/scripts/drugshortages). The primary record for §41.8's shortage discussion — current and resolved shortages, with dates and stated reasons. Use this instead of any secondary summary; the reasons given are more specific and more boring than the narratives built on them.

Bayer Co. v. United Drug Co., 272 F. 505 (S.D.N.Y. 1921). The aspirin genericide decision, and the founding text of Case Study 41.2's Case A. Short, readable, and startlingly relevant: the court's reasoning is about what the public understood the word to mean.

FDA safety communication and labeling actions on botulinum toxin products (2009), establishing distinct nonproprietary names and warning that potency units are not interchangeable between products. The regulatory response to a genericized name, and the closest thing to a precedent for the current case.

WHO International Nonproprietary Names (INN) program and the USAN Council stem lists. Referenced in Chapter 1 §1.8 and worth revisiting here: the systematic reason generic names are hard to say and the systematic reason they are worth saying anyway.

Tier 2 — Attributed, specifics unverified

Widely reported, frequently repeated, and not independently verified by this book. Treat every specific — dates, wordings, magnitudes — as provisional. Where a claim in this chapter rests on material from this tier, the chapter says so or declines to quantify.

The originating feature article for "Ozempic face." The term is consistently attributed to a dermatologist quoted in a US national newspaper feature published as these drugs entered mainstream coverage. The attribution is repeated nearly everywhere; the exact wording, the exact date, and whether the phrase was coined in that interview or merely popularized by it are not verified here. This is precisely the kind of origin claim that hardens through repetition, and Case Study 41.1 deliberately does not depend on its details.

Awards-show and late-night monologue coverage. Frequently cited as the moment the drug name became a mainstream punchline. Widely reported; the causal claim ("this is when it happened") is a narrative convenience and is not established.

Prescriber survey reporting on brand-name requests. Trade and general press have reported that clinicians increasingly receive requests by brand name for products that do not match the requested indication. The direction is consistent across reports; no methodology has been verified here, and §41.2's rating explicitly notes the absence of a formal study.

Search-interest curves and prescription-trend charts. Circulated widely in business and health press. Some derive from real dispensing datasets, some from panel extrapolations, and the two are routinely presented identically. If you use one, find out which it is first — that is the exercise.

Reports of patients with type 2 diabetes unable to fill established prescriptions during the shortage period. Widely reported across multiple countries and consistent in direction. Magnitude, duration, and the share attributable to demand outside approved indications are not established here.

Compounded and gray-market product reporting. Regulatory warnings on compounded semaglutide products exist and are Tier 1 where cited directly; the journalism describing the scale of that market is Tier 2, and estimates vary by an order of magnitude between sources.

Tier 3 — Illustrative and constructed

Built for teaching. Real in structure, invented in detail. Do not cite these as findings.

• The five-rung genericization ladder (§41.1). A pedagogical device, not a linguistic taxonomy from the literature.
• The nine-observation table (§41.5). Composite. The individual readings are commonplace; the table is assembled to make the unfalsifiability visible in one view.
• The base-rate arithmetic (§41.3). The 80% figures are invented for the demonstration and correspond to no measurement. The structure of the result — most positives false at low prevalence — is a mathematical fact, not an empirical claim.
• The joke rung of the compression ladder (§41.6). This chapter's addition to Chapter 6's model.
• The Cultural Drift Log (dossier). A worksheet.
• The risk function in Case Study 41.2. A heuristic written to organize five real cases, not a validated model.

If you only do one thing

Open the FDA labels for two products that contain the same molecule and read them side by side.

Fifteen minutes. Look only at three things: the product identity, the indications and usage section, and the date of the most recent revision. Then say out loud the sentence you would use to describe each product to a clinician.

You will not use the brand name that way again, and you will have understood §41.2 more thoroughly than any amount of reading about it can achieve. Everything else in this chapter is downstream of the distinction those two documents make and the culture erased.